Vertex's diabetes cell therapy spurs insulin production in a half-dozen patients
www.fiercebiotech.com
Vertex could be “leading the path to insulin independence," according to analysts, after another batch of data showed that the off-the-shelf diabetes cell therapy stimulated insulin production in a | Vertex could be “leading the path to insulin independence," according to analysts, after another batch of data showed that the off-the-shelf diabetes cell therapy stimulated insulin production in all evaluable patients, and that two were now insulin independent.

This is a summary of a Phase 1/2 trial of a cell therapy meant to stimulate insulin production in diabetes patients. The top line is that it met its clinical endpoints and several of the patients no longer require external insulin dosing at all and their blood sugar is well managed. Vertex also has a number of follow-up therapies in the pipeline meant to improve upon this therapy.

I personally don’t have much experience in cell therapy, but the potential of a treatment like this is clear. We will see what the data looks like as this goes through the clinical trial pipeline and expands the patient population in Phase 3.